Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The incidence of death, myocardial infarction, or stroke was significantly lower among those who received prasugrel than among those who received ticagrelor, and the incidence of major bleeding was not significantly different between the two groups.
Product Name : Brilique
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 17, 2020
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase III THALES trial showed aspirin plus BRILINTA 90mg used twice daily for 30 days, resulted in a statistically significant and clinically meaningful reduction in the risk of the primary composite endpoint of stroke and death, compared to aspirin alon...
Product Name : Brilinta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 07, 2020
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AZ Unveils Detailed Data from THALES Trial
Details : The Phase III THALES results shows that a combination of twice daily Brilinta (ticagrelor) and daily aspirin reduced the rate of stroke and death by 17% after 30 days compared to aspirin alone in patients with acute ischemic stroke or transient ischemic ...
Product Name : Brilinta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 16, 2020
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approval by the US FDA was based on positive results from the THALES Phase III trial that showed aspirin plus Brilinta 90mg significantly reduced the rate of the composite of stroke and death compared to aspirin alone in patients with acute ischaemic...
Product Name : Brilinta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 11, 2020
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke
Details : BRILINTA reduced the risk of the composite of stroke and death after an acute ischemic stroke or transient ischemic attack.
Product Name : Brilinta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 27, 2020
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approval was based on positive results from the Phase III THEMIS trial. The trial showed a statistically significant reduction in the primary composite endpoint of MACE at 36 months with aspirin + Brilinta 60mg versus aspirin alone in patients with C...
Product Name : Brilinta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2020
Lead Product(s) : Ticagrelor,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
